ArticleOrphanet journal of rare diseases2026
Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease.
Alberto Lerario et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.